Mage-A4 Tcr Gene-Modified T Cells

Name: Mage-A4 Tcr Gene-Modified T Cells in Malignant Solid Tumors
Creator: Floatz
License: https://terminal.floatz.ai/terms

Malignant Solid Tumors

Tianjin Medical University Cancer Institute and HospitalCell therapyPhase 1Dormant

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

30 Active assets in the Malignant Solid Tumors cohort.

Asset / Sponsor	Phase	Rating
Peg-Rhg-Csf CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Phase 4	B
Zofran The First Affiliated Hospital of Xinxiang Medical College	Phase 3	B
Medroxyprogesterone acetate The First Affiliated Hospital of Xinxiang Medical College	Phase 3	B
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- The First Affiliated Hospital of Xinxiang Medical College	Phase 3	B
DEXAMETHASONE The First Affiliated Hospital of Xinxiang Medical College	Phase 3	B

View all 38 →

Order a full diligence report on this asset.

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.